The Independent Data Safety Monitoring Board Has Issued Its Fourth Consecutive Positive Recommendation Following Review Of Safety Data From BriaCell Therapeutics' Phase 3 Study Of Bria-IMT Plus An Immune Checkpoint Inhibitor For Metastatic Breast Cancer

Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell's ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.